BACKGROUND: The use of perioperative dexamethasone has been proven to reduce pain and shorten recovery for patients undergoing total hip and knee arthroplasty. However, the effect of these medications on 90-day readmissions and the rates of clinically significant venous thromboembolic events (VTE) after total joint arthroplasty (TJA) remains unknown. METHODS: Patients undergoing unilateral, primary total joint arthroplasty between 2009 and 2016 in a single institution were identified. There were 6617 patients who did not receive dexamethasone intraoperatively compared to 1293 patients who received a single, intraoperative, intravenous dose of dexamethasone (8-10 mg). The primary outcomes were the rate of clinically significant VTE and 90-day readmission. Secondary outcomes included wound complications, periprosthetic joint infection, and 90-day mortality. RESULTS: While the overall rate of clinically symptomatic VTE was lower in the dexamethasone group, this did not reach significance in a univariate analysis (0.1% vs 0.2%, P = .353). Only body mass index (odds ratio [OR], 1.13; 95% confidence interval [CI], 1.03-1.24; P = .006) and longer length of stay (OR, 1.16; 95% CI, 1.06-1.28; P = .001) were associated with VTE in the multivariate analysis (OR, 0.31; 95% CI, 0.04-2.36; P = .319). However, the use of intravenous dexamethasone was independently associated with a reduction in 90-day readmission rate (1.6% vs 2.5%; OR, 0.57; 95% CI, 0.36-0.90; P = .016). There was no difference in the rate of periprosthetic joint infection or mortality. CONCLUSION: A single, intraoperative, low dose of dexamethasone is not associated with a reduction in clinically significant VTE but may be a safe and effective adjunct medication to lower 90-day readmission rates. LEVEL OF EVIDENCE: Level III.
BACKGROUND: The use of perioperative dexamethasone has been proven to reduce pain and shorten recovery for patients undergoing total hip and knee arthroplasty. However, the effect of these medications on 90-day readmissions and the rates of clinically significant venous thromboembolic events (VTE) after total joint arthroplasty (TJA) remains unknown. METHODS:Patients undergoing unilateral, primary total joint arthroplasty between 2009 and 2016 in a single institution were identified. There were 6617 patients who did not receive dexamethasone intraoperatively compared to 1293 patients who received a single, intraoperative, intravenous dose of dexamethasone (8-10 mg). The primary outcomes were the rate of clinically significant VTE and 90-day readmission. Secondary outcomes included wound complications, periprosthetic joint infection, and 90-day mortality. RESULTS: While the overall rate of clinically symptomatic VTE was lower in the dexamethasone group, this did not reach significance in a univariate analysis (0.1% vs 0.2%, P = .353). Only body mass index (odds ratio [OR], 1.13; 95% confidence interval [CI], 1.03-1.24; P = .006) and longer length of stay (OR, 1.16; 95% CI, 1.06-1.28; P = .001) were associated with VTE in the multivariate analysis (OR, 0.31; 95% CI, 0.04-2.36; P = .319). However, the use of intravenous dexamethasone was independently associated with a reduction in 90-day readmission rate (1.6% vs 2.5%; OR, 0.57; 95% CI, 0.36-0.90; P = .016). There was no difference in the rate of periprosthetic joint infection or mortality. CONCLUSION: A single, intraoperative, low dose of dexamethasone is not associated with a reduction in clinically significant VTE but may be a safe and effective adjunct medication to lower 90-day readmission rates. LEVEL OF EVIDENCE: Level III.